Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.38 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910457 | 0.79 | NR3C2 (0.38) | NR3C1PGRNR3C2MMP12ALDH1A1 | |
| SCHEMBL31170719 | 0.74 | IL4I1 (0.45) | IL4I1NR3C1PGRNR3C2MMP12 | |
| SCHEMBL20278370 | 0.72 | PDE3B (0.55) | IL4I1NR3C1PGRNR3C2MMP12 | |
| SCHEMBL8236302 | 0.72 | IL4I1 (0.44) | IL4I1NR3C1PGRNR3C2MMP12 | |
| SCHEMBL3600619 | 0.72 | IL4I1 (0.44) | IL4I1NR3C1PGRNR3C2MMP12 | |
| SCHEMBL4290482 | 0.72 | IL4I1 (0.44) | IL4I1NR3C1PGRNR3C2MMP12 | |
| SCHEMBL31170800 | 0.70 | CES1 (0.41) | IL4I1NR3C1PGRNR3C2MMP12 | |
| SCHEMBL5340556 | 0.70 | IL4I1 (0.43) | IL4I1NR3C1PGRNR3C2MMP12 | |
| SCHEMBL24869557 | 0.69 | NR3C1 (0.43) | IL4I1NR3C1PGRNR3C2MMP12 | |
| SCHEMBL8489457 | 0.69 | NR3C2 (0.44) | IL4I1NR3C1PGRNR3C2MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-05 | — | — | US | claimed |
| CN-115884773-A | Pharmaceutical preparation | 詹森药业有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-115210567-A | Methods of assessing efficacy of MALT1 inhibitors using NF-KB translocation assays | 詹森药业有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-114981453-A | NF-KB regulated gene expression assay for assessing efficacy of MALT1 inhibitors | 詹森药业有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-20220175760-A1 | PHARMACEUTICAL FORMULATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-09 | — | — | US | claimed |
| US-20210155990-A1 | NF-KB REGULATED GENE EXPRESSION ASSAY FOR ASSESSING EFFICACY OF MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-27 | — | — | US | claimed |
| US-20210156865-A1 | METHODS FOR ASSESSING EFFICACY OF MALT1 INHIBITORS USING AN NF-KB TRANSLOCATION ASSAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-27 | — | — | US | claimed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | claimed |
| CN-113473971-B | Pharmaceutical formulations | 詹森药业有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230414629-A1 | MATERIALS AND METHODS OF TREATING CANCER | MONOPTEROS THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-05 | — | — | US | disclosed |
| EP-4243812-A1 | MATERIALS AND METHODS OF TREATING CANCER | Monopteros Therapeutics, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230235077-A1 | MATERIALS AND METHODS OF TREATING CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-27 | — | — | US | disclosed |
| CN-115884773-A | Pharmaceutical preparation | 詹森药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20210155990-A1 | NF-KB REGULATED GENE EXPRESSION ASSAY FOR ASSESSING EFFICACY OF MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-27 | — | — | US | disclosed |
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-23 | — | — | US | disclosed |
| US-20210052596-A1 | TARGETING THE CBM SIGNALOSOME COMPLEX INDUCES REGULATORY T CELLS TO INFLAME THE TUMOR MICROENVIRONMENT | THE GENERAL HOSPITAL CORPORATION (US) | 2021-02-25 | — | — | US | disclosed |
| EP-3731848-A1 | TARGETING THE CBM SIGNALOSOME COMPLEX INDUCES REGULATORY T CELLS TO INFLAME THE TUMOR MICROENVIRONMENT | The General Hospital Corporation (US) | 2020-11-04 | — | — | EP | disclosed |
| CN-111770759-A | Targeting the CBM-signalosome complex to induce regulatory T cells to inflame the tumor microenvironment | 通用医疗公司 | 2020-10-13 | — | — | CN | disclosed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | IL4I1 1519/4885NR3C1 586/4885PGR 2789/4885 |
| US-20210052596-A1 | TARGETING THE CBM SIGNALOSOME COMPLEX INDUCES REGULATORY T CELLS TO INFLAME THE TUMOR MICROENVIRONMENT | CD47, ICOS, LCK | IL4I1 2165/4885NR3C1 1575/4885PGR 3296/4885 |
| US-20210155990-A1 | NF-KB REGULATED GENE EXPRESSION ASSAY FOR ASSESSING EFFICACY OF MALT1 INHIBITORS | MALT1, NFKBIA, NFKB2 | IL4I1 783/4885NR3C1 316/4885PGR 4571/4885 |
| US-20230235077-A1 | MATERIALS AND METHODS OF TREATING CANCER | MALT1, CD274, TP53 | IL4I1 2913/4885NR3C1 2310/4885PGR 3340/4885 |
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | MALT1, MGAM, MGLL | IL4I1 2608/4885NR3C1 459/4885PGR 3282/4885 |
| US-20220175760-A1 | PHARMACEUTICAL FORMULATIONS | TREH, F12, CEL | IL4I1 3455/4885NR3C1 3233/4885PGR 1736/4885 |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | MALT1, PPP3R1, SQSTM1 | IL4I1 1519/4885NR3C1 586/4885PGR 2789/4885 |
| US-20230414629-A1 | MATERIALS AND METHODS OF TREATING CANCER | MALT1, TP53, RAD1 | IL4I1 3202/4885NR3C1 2238/4885PGR 3710/4885 |
| US-20210156865-A1 | METHODS FOR ASSESSING EFFICACY OF MALT1 INHIBITORS USING AN NF-KB TRANSLOCATION ASSAY | NFKBIA, MALT1, NFATC1 | IL4I1 1438/4885NR3C1 352/4885PGR 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.